PURPOSE:Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lung cancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage SCLC (ES-SCLC). MATERIALS AND METHODS:Patients with ES-SCLC, stratified by sex and serum lactate dehydrogenase levels, were randomly assigned to receive four 3-week cycles of CE (75 mg/m2 intravenously on day 1 and 100 mg/m2 on days 1 through 3) along with veliparib (100 mg orally twice per day on days 1 through 7) or placebo (CE+P). The primary end point was progression-free survival (PFS). Using an overall one-sided 0.10-level log-rank test, the study had 88% power to demonstrate a 37.5% reduction in the PFS hazard rate. RESULTS: A total of 128 eligible patients received treatment on protocol. The median age was 66 years, 52% of patients were men, and Eastern Cooperative Oncology Group performance status was 0 for 29% of patients and 1 for 71%. The respective median PFS for the CE+V arm versus the CE+P arm was 6.1 versus 5.5 months (unstratified hazard ratio [HR], 0.75 [one-sided P = .06]; stratified HR, 0.63 [one-sided P = .01]), favoring CE+V. The median overall survival was 10.3 versus 8.9 months (stratified HR, 0.83; 80% CI, 0.64 to 1.07; one-sided P = .17) for the CE+V and CE+P arms, respectively. The overall response rate was 71.9% versus 65.6% (two-sided P = .57) for CE+V and CE+P, respectively. There was a significant treatment-by-strata interaction in PFS: Male patients with high lactate dehydrogenase levels derived significant benefit (PFS HR, 0.34; 80% CI, 0.22 to 0.51) but there was no evidence of benefit among patients in other strata (PFS HR, 0.81; 80% CI, 0.60 to 1.09). The following grade ≥ 3 hematology toxicities were more frequent in the CE+V arm than the CE+P arm: CD4 lymphopenia (8% v 0%; P = .06) and neutropenia (49% v 32%; P = .08), but treatment delivery was comparable. CONCLUSION: The addition of veliparib to frontline chemotherapy showed signal of efficacy in patients with ES-SCLC and the study met its prespecified end point.
RCT Entities:
PURPOSE:Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lung cancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage SCLC (ES-SCLC). MATERIALS AND METHODS:Patients with ES-SCLC, stratified by sex and serum lactate dehydrogenase levels, were randomly assigned to receive four 3-week cycles of CE (75 mg/m2 intravenously on day 1 and 100 mg/m2 on days 1 through 3) along with veliparib (100 mg orally twice per day on days 1 through 7) or placebo (CE+P). The primary end point was progression-free survival (PFS). Using an overall one-sided 0.10-level log-rank test, the study had 88% power to demonstrate a 37.5% reduction in the PFS hazard rate. RESULTS: A total of 128 eligible patients received treatment on protocol. The median age was 66 years, 52% of patients were men, and Eastern Cooperative Oncology Group performance status was 0 for 29% of patients and 1 for 71%. The respective median PFS for the CE+V arm versus the CE+P arm was 6.1 versus 5.5 months (unstratified hazard ratio [HR], 0.75 [one-sided P = .06]; stratified HR, 0.63 [one-sided P = .01]), favoring CE+V. The median overall survival was 10.3 versus 8.9 months (stratified HR, 0.83; 80% CI, 0.64 to 1.07; one-sided P = .17) for the CE+V and CE+P arms, respectively. The overall response rate was 71.9% versus 65.6% (two-sided P = .57) for CE+V and CE+P, respectively. There was a significant treatment-by-strata interaction in PFS: Male patients with high lactate dehydrogenase levels derived significant benefit (PFS HR, 0.34; 80% CI, 0.22 to 0.51) but there was no evidence of benefit among patients in other strata (PFS HR, 0.81; 80% CI, 0.60 to 1.09). The following grade ≥ 3 hematology toxicities were more frequent in the CE+V arm than the CE+P arm: CD4lymphopenia (8% v 0%; P = .06) and neutropenia (49% v 32%; P = .08), but treatment delivery was comparable. CONCLUSION: The addition of veliparib to frontline chemotherapy showed signal of efficacy in patients with ES-SCLC and the study met its prespecified end point.
Authors: Stein Sundstrøm; Roy M Bremnes; Stein Kaasa; Ulf Aasebø; Reidulv Hatlevoll; Ragnar Dahle; Nils Boye; Mari Wang; Tor Vigander; Jan Vilsvik; Eva Skovlund; Einar Hannisdal; Steinar Aamdal Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: Michèle Rouleau; Anand Patel; Michael J Hendzel; Scott H Kaufmann; Guy G Poirier Journal: Nat Rev Cancer Date: 2010-03-04 Impact factor: 60.716
Authors: Robert L Coleman; Michael W Sill; Katherine Bell-McGuinn; Carol Aghajanian; Heidi J Gray; Krishnansu S Tewari; Steven C Rubin; Thomas J Rutherford; John K Chan; Alice Chen; Elizabeth M Swisher Journal: Gynecol Oncol Date: 2015-03-24 Impact factor: 5.482
Authors: Nasser Hanna; Paul A Bunn; Corey Langer; Lawrence Einhorn; Troy Guthrie; Thaddeus Beck; Rafat Ansari; Peter Ellis; Michael Byrne; Mark Morrison; Subramanian Hariharan; Benjamin Wang; Alan Sandler Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Johann de Bono; Ramesh K Ramanathan; Lida Mina; Rashmi Chugh; John Glaspy; Saeed Rafii; Stan Kaye; Jasgit Sachdev; John Heymach; David C Smith; Joshua W Henshaw; Ashleigh Herriott; Miranda Patterson; Nicola J Curtin; Lauren Averett Byers; Zev A Wainberg Journal: Cancer Discov Date: 2017-02-27 Impact factor: 39.397
Authors: George Somlo; Paul H Frankel; Banu K Arun; Cynthia X Ma; Agustin A Garcia; Tessa Cigler; Leah V Cream; Harold A Harvey; Joseph A Sparano; Rita Nanda; Helen K Chew; Timothy J Moynihan; Linda T Vahdat; Matthew P Goetz; Jan H Beumer; Arti Hurria; Joanne Mortimer; Richard Piekarz; Sharon Sand; Josef Herzog; Lily R Van Tongeren; Katherine V Ferry-Galow; Alice P Chen; Christopher Ruel; Edward M Newman; David R Gandara; Jeffrey N Weitzel Journal: Clin Cancer Res Date: 2017-03-29 Impact factor: 12.531
Authors: Lauren Averett Byers; Jing Wang; Monique B Nilsson; Junya Fujimoto; Pierre Saintigny; John Yordy; Uma Giri; Michael Peyton; You Hong Fan; Lixia Diao; Fatemeh Masrorpour; Li Shen; Wenbin Liu; Boris Duchemann; Praveen Tumula; Vikas Bhardwaj; James Welsh; Stephanie Weber; Bonnie S Glisson; Neda Kalhor; Ignacio I Wistuba; Luc Girard; Scott M Lippman; Gordon B Mills; Kevin R Coombes; John N Weinstein; John D Minna; John V Heymach Journal: Cancer Discov Date: 2012-09-06 Impact factor: 39.397
Authors: Robert J G Cardnell; Christopher S Rabender; Gracious R Ross; Chunqing Guo; Eric L Howlett; Asim Alam; Xiang-Yang Wang; Hamid I Akbarali; Ross B Mikkelsen Journal: J Pharmacol Exp Ther Date: 2013-08-02 Impact factor: 4.030
Authors: Junko Murai; Shar-yin N Huang; Benu Brata Das; Amelie Renaud; Yiping Zhang; James H Doroshow; Jiuping Ji; Shunichi Takeda; Yves Pommier Journal: Cancer Res Date: 2012-11-01 Impact factor: 13.312
Authors: John T Poirier; Julie George; Taofeek K Owonikoko; Anton Berns; Elisabeth Brambilla; Lauren A Byers; David Carbone; Huanhuan J Chen; Camilla L Christensen; Caroline Dive; Anna F Farago; Ramaswamy Govindan; Christine Hann; Matthew D Hellmann; Leora Horn; Jane E Johnson; Young S Ju; Sumin Kang; Mark Krasnow; James Lee; Se-Hoon Lee; Jonathan Lehman; Benjamin Lok; Christine Lovly; David MacPherson; David McFadden; John Minna; Matthew Oser; Keunchil Park; Kwon-Sik Park; Yves Pommier; Vito Quaranta; Neal Ready; Julien Sage; Giorgio Scagliotti; Martin L Sos; Kate D Sutherland; William D Travis; Christopher R Vakoc; Sarah J Wait; Ignacio Wistuba; Kwok Kin Wong; Hua Zhang; Jillian Daigneault; Jacinta Wiens; Charles M Rudin; Trudy G Oliver Journal: J Thorac Oncol Date: 2020-02-01 Impact factor: 15.609
Authors: Renata Ferrarotto; Robert Cardnell; Shirley Su; Lixia Diao; A Karina Eterovic; Victor Prieto; William H Morrisson; Jing Wang; Merrill S Kies; Bonnie S Glisson; Lauren Averett Byers; Diana Bell Journal: Head Neck Date: 2018-03-23 Impact factor: 3.147
Authors: Anna F Farago; Beow Y Yeap; Marcello Stanzione; Yin P Hung; Rebecca S Heist; J Paul Marcoux; Jun Zhong; Deepa Rangachari; David A Barbie; Sarah Phat; David T Myers; Robert Morris; Marina Kem; Taronish D Dubash; Elizabeth A Kennedy; Subba R Digumarthy; Lecia V Sequist; Aaron N Hata; Shyamala Maheswaran; Daniel A Haber; Michael S Lawrence; Alice T Shaw; Mari Mino-Kenudson; Nicholas J Dyson; Benjamin J Drapkin Journal: Cancer Discov Date: 2019-08-15 Impact factor: 39.397
Authors: James Laird; Benjamin H Lok; Brandon Carney; Susanne Kossatz; Elisa de Stanchina; Thomas Reiner; John T Poirier; Charles M Rudin Journal: J Thorac Oncol Date: 2019-06-11 Impact factor: 15.609
Authors: Anish Thomas; Rasa Vilimas; Christopher Trindade; Rebecca Erwin-Cohen; Nitin Roper; Liqiang Xi; Venkatesh Krishnasamy; Elliot Levy; Andy Mammen; Samantha Nichols; Yuanbin Chen; Vamsidhar Velcheti; Faye Yin; Eva Szabo; Yves Pommier; Seth M Steinberg; Jane B Trepel; Mark Raffeld; Howard A Young; Javed Khan; Stephen Hewitt; Jung-Min Lee Journal: J Thorac Oncol Date: 2019-05-04 Impact factor: 15.609
Authors: Michael J Jelinek; Nathan R Foster; Alex J Zoroufy; Gary K Schwartz; Pamela N Munster; Tanguy Y Seiwert; Jonas A de Souza; Everett E Vokes Journal: Oral Oncol Date: 2021-01-26 Impact factor: 5.337
Authors: Zhicheng Niu; Shenghu Guo; Jing Cao; Yuehua Zhang; Xiaojin Guo; Francesco Grossi; Yoshinobu Ichiki; You Li; Zhiyu Wang Journal: Ann Transl Med Date: 2021-04